Search General Info
Search Education
Search Partnering Companies
![CEO 2023 Logo](/sites/default/files/2022-08/264423_BIO_22_CEO_Logo-V.png)
Antabio is developing a pipeline of novel antibacterial drugs targeting WHO critical priority pathogens for treatment of life-threatening lung infections .
SBLi our lead program entering phase 1 is a novel broad-spectrum treatment addressing a major gap in HAP/VAP not covered by existing standard of care, with blockbuster potential and eligibility for major market incentives that are underway. PEi our second program addresses non-CF bronchiectasis.
Antabio's team includes former management and executives from Novexel, GSK, Merck and AstraZeneca with strong track records.
The company has attracted substantial non-dilutive funding from major global organizations, including multi-million $ awards from the Wellcome Trust and CARB-X and more recently $15m blended funding from French “ARPEGE” and the EIC to be received in 2023 and beyond.
We are raising a series B of $23m to finance the company through the end of 2025 and complete SBLi Phase 2 and PEi Phase 1a SAD.
SBLi our lead program entering phase 1 is a novel broad-spectrum treatment addressing a major gap in HAP/VAP not covered by existing standard of care, with blockbuster potential and eligibility for major market incentives that are underway. PEi our second program addresses non-CF bronchiectasis.
Antabio's team includes former management and executives from Novexel, GSK, Merck and AstraZeneca with strong track records.
The company has attracted substantial non-dilutive funding from major global organizations, including multi-million $ awards from the Wellcome Trust and CARB-X and more recently $15m blended funding from French “ARPEGE” and the EIC to be received in 2023 and beyond.
We are raising a series B of $23m to finance the company through the end of 2025 and complete SBLi Phase 2 and PEi Phase 1a SAD.
![](/sites/default/files/hubb_images/6588/attachments/%2520-%2520f1_Antabio_106a7d87.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
2009
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
ANT3310-MEM, novel broad-spectrum treatment of drug-resistant nosocomial pneumonia
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
![photo](/sites/default/files/hubb_images/6588/photos/user1.Lemonnier.9c5629d4.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved